Author

L. R. P. Ferreira

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

B. Anonye· 1 shared C. B. Moraes· 1 shared D. F. Sales-Medina· 1 shared E. L. Durigon· 1 shared G. Courtemanche· 1 shared K. R. Goncalves· 1 shared L. Freitas Junior· 1 shared L. M. D. Romera· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

B. Anonye

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

MicrobiologybioRxivPreprintJan 30, 2023

Dual RNA-seq identifies proteins and pathways modulated during Clostridioides difficile colonisation

L. R. Frost, R. Stark, B. Anonye…·M. Unnikrishnan

This study uses dual RNA-seq to analyze gene expression changes in Clostridioides difficile and human gut epithelial cells during early infection, identifying modulated pathways and proteins involved in colonization.

DOI 10.1101/2023.01.30.526182

humanbulk RNA-seq

𝕏 PostBluesky

MicrobiologybioRxivPreprintJul 9, 2020

Discovery of clinically approved drugs capable of inhibiting SARS-CoV-2 in vitro infection using a phenotypic screening strategy and network-analysis to predict their potential to treat covid-19

D. F. Sales-Medina, L. R. P. Ferreira, L. M. D. Romera…·L. Freitas Junior

The paper identifies four drugs that inhibit SARS-CoV-2 in vitro infection through phenotypic screening and network analysis, providing insights for clinical repurposing.

DOI 10.1101/2020.07.09.196337

humanexperimental assay

𝕏 PostBluesky